IQVIA Holdings Inc. (IQV) Balance Sheet

The balance sheet is expanding rapidly, with assets up from $26.6B in 2024Q1 to $29.9B in 2026Q2, driven largely by acquisitions that added $2.1B in goodwill over the period. However, debt has grown at a similar pace, suggesting that growth is increasingly leveraged. The trajectory appears to be one of aggressive inorganic expansion, which may strain financial flexibility if organic growth slows.

The company's leverage is substantial, with debt-to-equity at 2.58x and debt-to-assets at 54%, far exceeding peers like ICON (0.39x D/E). This high leverage appears strategic, funding M&A to build the data moat, but it also increases sensitivity to interest rate hikes and any downturn in biopharma R&D spending. The modest cash position relative to debt implies refinancing risk, though strong operating cash flow (OCF/NI ~2.1x) provides some comfort.

The asset base is heavily weighted toward goodwill and intangibles, which have grown from $14.5B in 2024Q1 to $16.6B in 2026Q2, reflecting a series of acquisitions. This raises impairment risk if growth expectations falter, especially in the TAS segment. In contrast, net PPE is modest at $851M, indicating an asset-light operational model, but the intangible-heavy structure means reported earnings are depressed by amortization, masking underlying cash generation.

Equity quality appears solid, driven by retained earnings growth of $3.0B over ten quarters, which offsets the dilutive impact of stock-based compensation and buybacks. However, the company has deployed over $3.3B on share repurchases, which may have been funded by debt, as equity growth lags asset growth. The retained earnings build suggests operational profitability, but the high leverage means equity is a thin cushion against asset write-downs.

Liquidity is strained, with current liabilities exceeding current assets, a trend that has worsened over the past two years. The quick ratio is likely below 0.7, given inventory is minimal, leaving little room for working capital shocks. However, the company generates robust operating cash flow (TTM FCF ~$3.1B), which provides a buffer, but the reliance on debt markets for refinancing remains a key risk.